Loading stock data…
CUE
$30.44+1.36 (+4.68%)
Pre-Market$30.14-0.30 (-0.99%)· Last close Jun 9
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cue Biopharma, Inc. in the Healthcare sector is trading at $30.44 with a market capitalization of $128M. Wall Street consensus targets $115.00 (1 analysts), implying a +277.8% move over the next 12 months. The stock is currently 27% below its 52-week high of $41.42, remaining 80.2% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +277.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.69M↓ | $21.94M↑ | $2.15M↓ | $2.95M↑ | $421,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.36M↓ | $1.96M↑ | -$7.54M↑ | -$8.63M↑ | -$12.30M |
| Net Income | -$5.18M↓ | $1.58M↑ | -$7.45M↑ | -$8.48M↑ | -$12.26M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$127.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-90.35%
Volume
Today's trading volume
43,314
Recent News
Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEO
Cue Biopharma Inc. (NASDAQ:CUE) is one of the 10 Unstoppable Stocks That Could Double Your Money. Cue Biopharma Inc. (NASDAQ:CUE) is one of the unstoppable stocks that could double your money. On March 27, Cue Biopharma announced a leadership transition, appointing Lucinda Warren as interim president and chief executive officer. Warren, who joined the company […]
The VIX Sharply Reverses and Points Back Towards 30 After Failed Peace Negotiations
The CBOE Volatility Index (VIX) is reversing sharply this Monday morning, spiking more than 7% after weekend negotiations between the U.S. and Iran collapsed following 21 hours of talks, sending the fear gauge back toward the 30 threshold it breached two weeks ago. The VIX closed at 19.23 on April 10, sitting in the normal ... The VIX Sharply Reverses and Points Back Towards 30 After Failed Peace Negotiations
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.00% and -14.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of -23.53% and -69.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +133.33% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?